Contact Us
Drug Search Results
More Filters [+]

Cilnidipine

Alternative Names: cilnidipine
Latest Update: 2024-09-09
Latest Update Note: News Article

Product Description

Cilnidipine is a new antihypertensive drug distinguished from other L-type Ca2+ channel blockers or even other antihypertensives, which will be useful for selection of antihypertensive drugs according to the pathophysiological condition of a patient. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905258/)

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Orphan Drug - Scleroderma, General *

Approval Status: Not Approved

Approved Countries: Bangladesh | India | Japan | Korea | Philippines | Portugal | Sri Lanka | United Arab Emirates | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: IlDong Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cilnidipine

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Raynaud Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
RECONNOITER-1

P2

Recruiting

Raynaud Disease

2022-12-31

Recent News Events

Date

Type

Title

09/09/2024

News Article

 AISA Pharma Receives FDA Orphan Drug Designation for AISA-021 for Treatment of Systemic Sclerosis

04/01/2024

PubMed

 Effects of 1,4-dihydropyridine derivatives on cell injury and mTOR of HepG2 and 3D-QSAR study.

02/01/2024

PubMed

 Supersulfide prevents cigarette smoke extract-induced mitochondria hyperfission and cardiomyocyte early senescence by inhibiting Drp1-filamin complex formation.

01/01/2024

PubMed

 The Promise of Cilnidipine in Hypertension with Comorbidities: National Consensus Statement: National Consensus Group Comprises Cardiologists, Nephrologists, and Diabetologists from India in a National Meet at New Delhi held on 22(nd) May 2022.

09/26/2023

News Article

 Robot Battery Market 2023 Size, Growth Trends, Revenue, Future Plans and Forecast 2029

06/21/2023

News Article

 AISA Pharma Announces Start of Phase 2b Profervia® Study for Raynaud's Phenomenon in Systemic Sclerosis (SSc)

04/03/2023

News Article

 AISA Pharma Announces NIH-NINDS Award to investigate Profervia® as a non-opioid analgesic for acute and chronic pain

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions